Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
2000-04-25
Hutzell, Paula K.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303882, 53038822, 5303888, 530395, C07K 1618, C07K 1628, C07K 1630, C07K 1632
Patent
active
060545615
ABSTRACT:
Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell expressing an antigen selected from the group consisting of high molecular weight mucins bound by 2G3 and 369F10, c-erbB-2 tumor antigen, an approximately 42 kD glycoprotein, an approximately 55 kD glycoprotein, and the approximately 40, 60, 100 and 200 kD antigens bound by 113F1. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V.sub.H and V.sub.L domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
REFERENCES:
patent: Re35491 (1997-04-01), Cline et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4938948 (1990-07-01), Ring et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5629197 (1997-05-01), Ring et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
Benkar, I et al. PMAS USA 91(25):12051-5, 1994.
Diegel, ML et al. AIDS Res. Human Retroviruses 9(5): 465-73, 1993.
Padlan, EA. Mol. Immunol. 28(4/5):489-498, 1991.
Huston et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia coli," Proc. Natl. Acad. Sci. (USA) (1988) 85:5879-5883.
Riechmann et al., "Reshaping Human Antibodies for Therapy," Nature (1988) 332:323-327.
Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2," Molecular Immunology (1991) 28(8):915-917.
Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilyxozyme Activity," Science (1988) 239:1534-1536.
Allen et al., "Microvillin: A 200-Kilodalton Protein in Microvilli of Rat Mammary Cells Detected by a Monoclonal Antibody," Proc. Natl. Acad. Sci. USA 81:5459-5463 (1984).
Carter et al., "Humanization of an Anti-p185.sup.HER2 Antibody for Human Cancer Therapy," Proc. Natl. Acad. Sci. USA 89:4285-4289 (1992).
Cohen et al., "Expression Pattern on neu (NGL) Gene-Encoded Growth Factor Receptor Protein (p185.sup.neu) in Normal and Transformed Epithelial Tissues of the Digestive Tract," Oncogene 4:81-88 (1989).
Colcher et al., "A Spectrum of Monoclonal Antibodies Reactive with Human Mammary Tumor Cells," Proc. Natl. Acad. Sci USA 3:3199-3203 (1981).
Drebin et al., "Monoclonal Antibodies Identify a Cell-Surface Antigen Associated With an Activated Cellular Oncogene," Nature 312:545-548 (1984).
Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies," Cell 41:695-706 (1985).
Drebin et al., "Development of Monoclonal Antibodies Reactive with the Product of the neu Oncogene," Immunology and Cancer (Kripke et al., eds., the University of Texas Press, Austin) vol. 38, Chapter 18, pp. 277-289 (1986).
Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product," Cancer Research 50:1550-1558 (1990).
Gullick et al., "Expression of the c-erbB-2 Protein in Normal and Transformed Cells," Int. J. Cancer 40:246-254 (1987).
Hand et al., "Definition of Antigenic Heterogeneity and Modulation Among Human Mammary Carcinoma Cell Populations Using Monoclonal Antibodies to Tumor-Associated Antigens," Cancer Research 43:728-735 (1983).
Hudziak et al.; "p185.sup.HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor," Molecular and Cellular Biology 9(3):1165-1172 (1989).
Kennel et al., "Direct Binding of Radioiodinated Monoclonal Antibody to Tumor Cells: Significance of Antibody Purity and Affinity for Drug Targeting or Tumor Imaging," Hybridoma 2(3):297-310 (1983).
Kennel et al., "Tumor Antigen on Benign Adenomas and on Murine Lung Carcinomas Quantitated by a Two-Site Monoclonal Antibody Assay," Cancer Research 46:707-712 (1986).
Loop et al., "Two Human Tumor-Associated Antigens, p155 and p210, Detected by Monoclonal Antibodies," Int. J. Cancer 27:775-781 (1981).
Padhy et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas," Cell 28:865-871 (1982).
Ring et al., "Distribution and Physical Properties of BCA200, a M.sub.r 200,000 Glycoprotein Selectively Associated with Human Breast Cancer," Cancer Research 49:3070-3080 (1989).
Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2," Molecular Immunology 28(8):915-917 (1991).
Schechter et al., "The neu Oncogene: an erb-B-related Gene Encoding a 185,000-M.sub.r Tumour Antigen," Nature 312:513-516 (1984).
Stramignoni et al., "Differential Reactivity of Monoclonal Antibodies with Human Colon Adenocarcinomas and Adenomas," J. Cancer 31:543-552 (1983).
Bansal Geetha P.
Blackburn Robert P.
Chiron Corporation
Guth Joseph H.
Hutzell Paula K.
LandOfFree
Antigen-binding sites of antibody molecules specific for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen-binding sites of antibody molecules specific for cancer , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen-binding sites of antibody molecules specific for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-994292